Two biotech companies, Faeth Therapeutics and Climb Bio, have been selected as stock picks. These companies have seen their stock prices drop significantly over the last 60 days. Climb Bio received a buy rating and a price target from Deutsche Bank.
Read the full story from NKyTribune.